依那普利杂质8 | 76391-23-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 依那普利杂质8
• 英文名称: R9UX8SQ7BZ
• 英文别名: (2S)-1-[(2S)-2-[[(1R)-1-carboxy-3-phenylpropyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
• CAS: 76391-23-6
• 化学式: C₁₈H₂₄N₂O₅
• 分子量: 348.4
• InChiKey: LZFZMUMEGBBDTC-CFVMTHIKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Process for preparation of carboxyalkyldipeptide derivatives
  申请人：Merck & Co., Inc.

  公开号：EP0079521A1

  公开（公告）日：1983-05-25

  A process for the preparation of carboxyalkyldipeptide compounds of the Formula is described wherein R6 is hydroxy, loweralkoxy, or amino; R, R2 and R7 are hydrogen or loweralkyl; R3 is, e.g., hydrogen, or loweralkyl, R' is, e.g., hydrogen, or alkyl of from 1 to 20 carbon atoms, R4 is hydrogen or loweralkyl, R5 is, e.g., hydrogen, or loweralkyl, and, R4 and R5 may be connected together to form an alyklene bridge of from 2 to 4 carbon atoms. The process comprises reacting a compound of the Formula with a dipeptide (or protected dipeptide) of the Formula and an alkali metal cyanide or a trimethylsilycyanide, to form an amino nitrile compound of the Formula followed by hydrolysis. These compounds are useful as converting enzyme inhibitors and as antihypertensive agents.

  描述了一种制备Formula的羧基烷基二肽化合物的过程，其中R6为羟基、低烷氧基或氨基；R、R2和R7为氢或低烷基；R3为氢、低烷基等；R'为氢、1-20碳原子的烷基等；R4为氢或低烷基；R5为氢、低烷基等，R4和R5可以连接在一起形成2-4个碳原子的烷基桥。该过程包括将Formula的化合物与Formula的二肽（或保护的二肽）和碱金属氰化物或三甲基硅氰化物反应，形成Formula的氨基腈化合物，然后进行水解。这些化合物可用作转化酶抑制剂和降压剂。
• Enalapril formulations
  申请人：Silvergate Pharmaceuticals, Inc.

  公开号：US10772868B2

  公开（公告）日：2020-09-15

  Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.

  本文提供了稳定的依那普利口服液制剂。本文还提供了使用依那普利口服液制剂治疗某些疾病（包括高血压、心力衰竭和无症状左心室功能障碍）的方法。
• ENALAPRIL FORMULATIONS
  申请人：Silvergate Pharmaceuticals, Inc.

  公开号：US20190142797A1

  公开（公告）日：2019-05-16

  Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.